Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine Block for Gastroesophageal Reflux Disease
NCT06304142Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Randomised, single-blind trial of lidocaine in gastroesophageal reflux disease (GERD) (2 arms). Primary endpoint: Gastroesophageal Reflux Disease Questionnaire at day 10. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06304142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304142.